亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Hair Repigmentation During Immunotherapy Treatment With an Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Agent for Lung Cancer

医学 肺癌 不利影响 无容量 皮肤病科 皮肤癌 免疫疗法 内科学 肿瘤科 癌症
作者
Noemi Rivera,Aram Boada,María Isabel Bielsa,María Teresa Fernández‐Figueras,Enric Carcereny,María Teresa Cabero Morán,Carlos Ferrándiz
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:153 (11): 1162-1162 被引量:69
标识
DOI:10.1001/jamadermatol.2017.2106
摘要

Importance

New targeted therapies for cancer have been released in recent years, opening new horizons in the treatment of patients with cancer. However, their related adverse events (AE) are not fully characterized. Hair repigmentation (HR) is a nondescribed effect secondary to anti–programmed cell death 1 (anti–PD-1) and anti–programmed cell death ligand 1 (anti–PD-L1 ) therapy for treatment of lung cancer (LC), in opposition to the vitiligo reactions that develop during melanoma treatment.

Objective

To describe a new adverse event occurring during anti–PD-1/anti–PD-L1 therapy for LC.

Design, Setting, and Participants

A case series from a descriptive observation of 14 patients with HR after anti–PD-1/anti–PD-L1 treatment, recruited between September and December, 2016, who were followed up to detect whether they developed cutaneous AE at the time HR was detected. The patients had all been treated in the dermatology department at Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Main Outcomes and Measures

Clinical observation of HR during anti–PD-1/anti–PD-L1 therapy for LC, proved by comparing old pictures provided by the patients and recent pictures taken during the follow-up.

Results

Fourteen patients (13 men and 1 woman; mean age, 64.9 years) receiving anti–PD-1 or anti–PD-L1 therapy for non–small-cell lung cancer (NSCLC) presented hair repigmentation during follow-up. This hair repigmentation consisted in a diffuse darkening of the hair in 13 of 14 patients, or in black patches between white hairs in 1. Thirteen of 14 patients presented a good clinical response to the treatment, with at least stable disease, and only 1 had to stop the therapy after only 4 cycles of treatment owing to a life-threatening progression of the disease.

Conclusions and Relevance

We present to our knowledge the first report of hair repigmentation owing to anti–PD-1/anti–PD-L1 therapy for lung cancer in a series of 14 patients. Hair repigmentation may be a good response marker in patients receiving anti-PD1/anti–PD-L1 therapy for LC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爱吃百香果完成签到,获得积分10
2秒前
zhuzhu发布了新的文献求助10
3秒前
20秒前
夜雨完成签到,获得积分10
30秒前
Lynne完成签到,获得积分10
33秒前
33秒前
41秒前
zhuzhu发布了新的文献求助10
47秒前
frap完成签到,获得积分10
50秒前
今天开心吗完成签到 ,获得积分10
53秒前
钱塘郎中完成签到,获得积分0
57秒前
1分钟前
聪明的云完成签到 ,获得积分10
1分钟前
长城干红完成签到 ,获得积分0
1分钟前
1分钟前
justsoso完成签到,获得积分10
1分钟前
rocky15应助Tsingyuan采纳,获得10
1分钟前
zhuzhu发布了新的文献求助10
1分钟前
1分钟前
1分钟前
laihuimin完成签到,获得积分10
1分钟前
从容访旋发布了新的文献求助10
1分钟前
丘比特应助白瓜采纳,获得10
1分钟前
1分钟前
1分钟前
souther完成签到,获得积分0
1分钟前
1分钟前
Tsingyuan完成签到,获得积分10
1分钟前
1分钟前
doctorw完成签到 ,获得积分10
1分钟前
从容访旋完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
白瓜发布了新的文献求助10
2分钟前
秋雪瑶应助从容访旋采纳,获得10
2分钟前
2分钟前
2分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
行動データの計算論モデリング 強化学習モデルを例として 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545225
求助须知:如何正确求助?哪些是违规求助? 2175592
关于积分的说明 5600078
捐赠科研通 1896314
什么是DOI,文献DOI怎么找? 946171
版权声明 565327
科研通“疑难数据库(出版商)”最低求助积分说明 503541